BioSpace News Archive

- Presentation with live audio webcast to be held Tuesday, March 20 at 3:20 p.m. ET-

Cardiac troponin I (cTnI) concentrations measured with the Singulex ultrasensitive cTnI assay, powered by Single Molecule Counting technology, were associated with a higher prevalence of coronary artery disease (CAD) and independently predicted cardiovascular events in patients with obstructive and non-obstructive CAD, according to a study published in the Journal of the American Heart Association.

Collaboration combines best-in-class offerings from CHA and PAREXEL to enhance early phase clinical trials in growing hub for drug development

Advancing Escalier’s drug candidates through human proof-of-concept studies

Using needle-free device after significant increase in neutralizing antibody response in pre-clinical trials

Axel Schleyer, Ph.D. named Senior Vice President of Business Development, North America; Christoph Winterhalter, Ph.D. named Senior Vice President of Business Development, Europe

A team of researchers at IBBR is showing how engineered multi-specific antibodies appear to be highly effective at preventing infection across a broad range of HIV-1 virus strains.

In response to the injectables shortage, a growing number of large hospice organizations and their pharmacists are adopting the rectal route of administration thanks to a nurse who invented a device (the Macy Catheter) to make rectal administration discreet, painless, and reliable.

Pharmahungary Group launches online version of miRNAtarget: new software tool for the analysis of mRNA targets of differentially expressed microRNAs (miRNAs).

− Second of two pivotal Phase 3 studies (ELARIS UF-II) met primary efficacy endpoint and all ranked secondary endpoints − Results were consistent with the first Phase 3 study (ELARIS UF-I) and demonstrated elagolix, in combination with low-dose add-back therapy, reduced heavy menstrual bleeding compared to placebo − Data will be presented at an upcoming medical conference